LOGIN  |  REGISTER
Cue Biopharma
Terns Pharmaceuticals

Codexis to Participate in Upcoming Healthcare Conferences

September 03, 2024 | Last Trade: US$3.23 0.13 4.19

REDWOOD CITY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in two upcoming investor conferences.

The Cantor Global Healthcare Conference (New York, NY)

  • Tuesday, September 17, 2024, at 11:30 am ET, management will participate in a fireside chat

The Craig-Hallum Bioprocessing Conference (Virtual)

  • Thursday, September 19, 2024, at 2:00 pm ET, management will participate in a fireside chat

A live webcast of the Cantor fireside chat will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay of the Craig-Hallum fireside chat will be available in the same location within 48 hours of the presentation. A replay of each will be archived for at least 90 days following the presentation date.

About Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.

For More Information

Investor Contact
Carrie McKim
(336) 608-9706
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Lauren Musto
(650) 421-8205
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB